Novakand Pharma AB (publ)

OM:NOVKAN Stock Report

Market Cap: SEK 27.4m

Novakand Pharma Management

Management criteria checks 3/4

Novakand Pharma's CEO is Peter Selin, appointed in Jul 2023, has a tenure of 2.25 years. total yearly compensation is SEK2.55M, comprised of 78.6% salary and 21.4% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth SEK52.32K. The average tenure of the management team and the board of directors is 1.1 years and 15.8 years respectively.

Key information

Peter Selin

Chief executive officer

SEK 2.6m

Total compensation

CEO salary percentage78.62%
CEO tenure2.3yrs
CEO ownership0.2%
Management average tenure1.1yrs
Board average tenure15.8yrs

Recent management updates

Recent updates

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Aug 13
Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Dec 06
We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

Jul 19
Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Mar 08
Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Jun 29
We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Mar 08
We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

Aug 02
Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Apr 06
We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

CEO Compensation Analysis

How has Peter Selin's remuneration changed compared to Novakand Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-SEK 40m

Mar 31 2025n/an/a

-SEK 45m

Dec 31 2024SEK 3mSEK 2m

-SEK 45m

Sep 30 2024n/an/a

-SEK 53m

Jun 30 2024n/an/a

-SEK 53m

Mar 31 2024n/an/a

-SEK 60m

Dec 31 2023SEK 3mSEK 2m

-SEK 65m

Compensation vs Market: Peter's total compensation ($USD270.42K) is about average for companies of similar size in the Swedish market ($USD303.58K).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.

CEO

Peter Selin (52 yo)

2.3yrs
Tenure
SEK 2,554,000
Compensation

Mr. Peter Selin serves as Chief Executive Officer of Novakand Pharma AB (publ) (formerly known as Kancera AB (publ)) since July 1, 2023. He had been an Executive Vice president of Corporate Development & F...

Leadership Team

NamePositionTenureCompensationOwnership
Peter Selin
Chief Executive Officer2.3yrsSEK 2.55m0.19%
SEK 52.3k
Thomas Olin
Executive VP & Director1.1yrsSEK 150.00k0.30%
SEK 81.3k
Hans Richter
Chief Financial Officerno datano datano data
Robert Edfors
Chief Medical Officerless than a yearno datano data
1.1yrs
Average Tenure
67yo
Average Age

Experienced Management: NOVKAN's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Thomas Olin
Executive VP & Director15.8yrsSEK 150.00k0.30%
SEK 81.3k
Erik Nerpin
Independent Chairman of the Board15.8yrsSEK 200.00k0.24%
SEK 65.4k
Anders Gabrielsen
Independent Director7.2yrsSEK 150.00kno data
15.8yrs
Average Tenure
64yo
Average Age

Experienced Board: NOVKAN's board of directors are seasoned and experienced ( 15.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/30 16:24
End of Day Share Price 2025/10/30 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novakand Pharma AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Johan StromqvistABG Sundal Collier Sponsored
Martin WahlstromRedeye
Filip LindkvistRedeye